0000920465-18-000002.txt : 20180103 0000920465-18-000002.hdr.sgml : 20180103 20180103215543 ACCESSION NUMBER: 0000920465-18-000002 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171229 FILED AS OF DATE: 20180103 DATE AS OF CHANGE: 20180103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Douglass Laura L. CENTRAL INDEX KEY: 0001589362 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36282 FILM NUMBER: 18508346 MAIL ADDRESS: STREET 1: C/O LA JOLLA PHARMACEUTICAL COMPANY STREET 2: LA JOLLA VILLAGE DRIVE, SUITE 1070 CITY: SAN DIEGO STATE: CA ZIP: 92122 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LA JOLLA PHARMACEUTICAL CO CENTRAL INDEX KEY: 0000920465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330361285 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4550 TOWNE CENTRE COURT CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-207-4264 MAIL ADDRESS: STREET 1: 4550 TOWNE CENTRE COURT CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 wf-form4_151503452964254.xml FORM 4 X0306 4 2017-12-29 0 0000920465 LA JOLLA PHARMACEUTICAL CO LJPC 0001589362 Douglass Laura L. C/O LA JOLLA PHARMACEUTICAL COMPANY, 4550 TOWNE CENTRE COURT SAN DIEGO CA 92121 1 0 0 0 Common Stock 2017-12-29 4 M 0 6000 10.84 A 6000 D Common Stock 2017-12-29 4 M 0 4000 6 A 10000 D Common Stock 2017-12-29 4 S 0 10000 32.3208 D 0 D Stock Option (Right to Buy) 10.84 2017-12-29 4 M 0 6000 0 D 2024-04-03 Common Stock 6000.0 0 D Stock Option (Right to Buy) 6.0 2017-12-29 4 M 0 4000 0 D 2023-11-21 Common Stock 4000.0 14000 D Represents the average sale price, with individual sale prices ranging from $32.29 to $32.49 per share. The reporting person will provide the Staff of the Securities and Exchange Commission or a shareholder with individual sales price information, if requested. This option represents a right to purchase a total of 6,000 shares of the Issuer's Common Stock, one third of which shall be fully vested and exercisable on April 3, 2015, with the remaining 4,000 shares vesting quarterly thereafter over the next two years. These options represent a right to purchase a total of 18,000 shares of the Issuer's Common Stock, one quarter of which shall be fully vested and exercisable on October 14, 2014, with the remaining 13,500 shares vesting monthly thereafter over the next three years in 36 equal increments of 375 shares. /s/ Ryan Murr, by power of attorney for Laura L. Douglass 2018-01-03